BUSINESSFINANCIAL TIMES WORLD
US launches trade investigation into Germany’s spending on new medicines
The US has launched a Section 301 trade investigation targeting Germany's spending on new medicines, escalating tensions in Washington's drug pricing dispute with Europe.
Related Signal
Adjacent reporting
- US launches Germany pharma pricing probe, raising threat of new tariffs
- US probes Germany's 'persistent underpayment' for drugs
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
- US Proposes New Tariffs After Investigation; US, Iran Exchange Clashes | Bloomberg Brief 6/3/2026
- Campaigners threaten legal action over UK-US deal on prices NHS pays for drugs